TPC invests in MIGENIX’s new antibiotic drug

MIGENIX Inc of Vancouver has received $9.3 million from Technology Partnerships Canada to launch a $35.6-million R&D project to further develop its MX-2401 antibiotic drug. The project is intended to increase the drug’s efficacy against skin and soft tissue infections as well as the development of a cost-effective manufacturing process. Pre-clinical testing of MX-2401 — a lipopeptide-based compound derived from amphomycin — could demonstrate a low likelihood of rapid development of resistance and cross-resistance to many infections acquired in hospital....